Adverse Effects of Anastrozole in Patients With DCIS

Video

Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).

Brufsky mentions that the two main adverse effects are arthralgia and bone loss. Severe arthralgia occurs in only 10% of patients, and it typically alleviates on its own. There are ways to prevent bone loss as well.

Brufsky believes it would be beneficial to define the subtypes of DCIS that need little to no treatment.

Adam M.  Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content